Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[ plus ])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
Por:
Llombart-Cussac, A, Harper-Wynne, C, Perello, A, Hennequin, A, Fernandez, A, Colleoni, M, Carañana, V, Quiroga, V, Medioni, J, Iranzo, V, Wheatley, D, Del Barco, S, Anton, A, Dobi, E, Ruiz-Borrego, M, Alcalá-López, D, Pérez-Escuredo, J, Sampayo-Cordero, M, Pérez-García, JM and Cortes, J
Publicada:
1 jun 2023
Resumen:
Filiaciones:
Univ Catolica Valencia, Hosp Arnau Vilanova, Med Sci Innovat Res MEDSIR, Barcelona, Spain
Maidstone Hlth Author, Kent Oncol Ctr, Kent, OH USA
Hosp Univ Son Espases, Palma De Mallorca, Spain
Ctr Georges Francois Leclerc, Dijon, France
Inst Catala Oncol, Lhospitalet De Llobregat, Spain
Ist Europeo Oncol, Milan, MI, Italy
Univ Hosp Arnau de Vilanova, Lleida, Spain
Inst Catala Oncol Badalona, Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, GEICAM Spanish Breast Canc Grp, Badalona, Spain
Hop Europeen Georges Pompidou, Paris, France
Fundac Para Invest Hosp Gen Univ Valencia, Valencia, Spain
Royal Cornwall Hosp, Truro, England
ICO Josep Trueba, Girona, Spain
Hosp Univ Miguel Servet, CIBERONC ISCIII, GEICAM Spanish Breast Canc Grp, Zaragoza, Spain
Univ Hosp Ctr, Besancon, France
Hosp Virgen Rocio Sevilla, GEICAM Spanish Breast Canc Grp, Seville, Spain
Medica Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Sci Innovat Res MEDSIR, Quiron Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
|